# Trustmark Corp: financial statements, quarterly

TRMK · Nasdaq · CIK 36146 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/trmk.md) · [Financials](/companies/trmk/financials.md) · [Filings](/companies/trmk/filings.md) · [Insiders](/companies/trmk/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/trmk/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense | $m | [89.9](/filings/0000950170-23-060317.md) | [96.1 d](/filings/0000950170-24-015988.md) | [97.0](/filings/0000950170-24-054516.md) | [98.1](/filings/0000950170-24-091897.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [6.3](/filings/0000950170-24-121533.md) | [6.6 d](/filings/0001193125-26-064009.md) | [6.8](/filings/0000950170-25-064530.md) | [(37.7)](/filings/0000950170-25-103063.md) | [11.1](/filings/0001193125-25-267205.md) | [8.6 d](/filings/0001193125-26-064009.md) | [11.7](/filings/0001193125-26-209195.md) | [13.0](/filings/0001193125-26-335156.md) | [13.0](/filings/0001193125-25-267205.md) | [12.9 d](/filings/0001193125-26-064009.md) | [11.9](/filings/0001193125-26-209195.md) | [14.2](/filings/0001193125-26-335156.md) |
| Net income | $m | [34.0](/filings/0000950170-24-121533.md) | [36.1 d](/filings/0001193125-26-064009.md) | [41.5](/filings/0001193125-25-267205.md) | [73.8](/filings/0001193125-25-267205.md) | [51.3](/filings/0001193125-25-267205.md) | [56.3 d](/filings/0001193125-26-064009.md) | [53.6](/filings/0001193125-26-335156.md) | [55.8](/filings/0001193125-26-335156.md) | [56.8](/filings/0001193125-25-267205.md) | [57.9 d](/filings/0001193125-26-064009.md) | [56.1](/filings/0001193125-26-335156.md) | [63.5](/filings/0001193125-26-335156.md) |
| Diluted EPS | $ per share | [0.56](/filings/0000950170-24-121533.md) | not reported | [0.68](/filings/0000950170-25-064530.md) | [1.20](/filings/0000950170-25-103063.md) | [0.84](/filings/0001193125-25-267205.md) | not reported | [0.88](/filings/0001193125-26-209195.md) | [0.92](/filings/0001193125-26-335156.md) | [0.94](/filings/0001193125-25-267205.md) | not reported | [0.95](/filings/0001193125-26-209195.md) | [1.08](/filings/0001193125-26-335156.md) |
| Basic EPS | $ per share | [0.56](/filings/0000950170-24-121533.md) | not reported | [0.68](/filings/0000950170-25-064530.md) | [1.21](/filings/0000950170-25-103063.md) | [0.84](/filings/0001193125-25-267205.md) | not reported | [0.88](/filings/0001193125-26-209195.md) | [0.92](/filings/0001193125-26-335156.md) | [0.94](/filings/0001193125-25-267205.md) | not reported | [0.95](/filings/0001193125-26-209195.md) | [1.09](/filings/0001193125-26-335156.md) |

- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $bn | [18.4](/filings/0000950170-23-060317.md) | [18.7](/filings/0000950170-25-023184.md) | [18.4](/filings/0000950170-24-054516.md) | [18.5](/filings/0000950170-24-091897.md) | [18.5](/filings/0000950170-24-121533.md) | [18.2](/filings/0001193125-26-064009.md) | [18.3](/filings/0000950170-25-064530.md) | [18.6](/filings/0000950170-25-103063.md) | [18.8](/filings/0001193125-25-267205.md) | [18.9](/filings/0001193125-26-335156.md) | [19.0](/filings/0001193125-26-209195.md) | [19.2](/filings/0001193125-26-335156.md) |
| Total liabilities | $bn | [16.8](/filings/0000950170-23-060317.md) | [17.1](/filings/0000950170-25-023184.md) | [16.7](/filings/0000950170-24-054516.md) | [16.6](/filings/0000950170-24-091897.md) | [16.5](/filings/0000950170-24-121533.md) | [16.2](/filings/0001193125-26-064009.md) | [16.3](/filings/0000950170-25-064530.md) | [16.5](/filings/0000950170-25-103063.md) | [16.7](/filings/0001193125-25-267205.md) | [16.8](/filings/0001193125-26-335156.md) | [16.9](/filings/0001193125-26-209195.md) | [17.0](/filings/0001193125-26-335156.md) |
| Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [1.6](/filings/0000950170-24-121533.md) | [1.7](/filings/0001193125-26-064009.md) | [1.7](/filings/0001193125-25-267205.md) | [1.9](/filings/0001193125-25-267205.md) | [2.0](/filings/0001193125-25-267205.md) | [2.0](/filings/0001193125-26-335156.md) | [2.0](/filings/0001193125-26-335156.md) | [2.1](/filings/0001193125-26-335156.md) | [2.1](/filings/0001193125-25-267205.md) | [2.1](/filings/0001193125-26-335156.md) | [2.1](/filings/0001193125-26-335156.md) | [2.1](/filings/0001193125-26-335156.md) |

- Cash and equivalents: not reported
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [106 d](/filings/0000950170-24-121533.md) | [64.2 d](/filings/0001193125-26-064009.md) | [(58.5)](/filings/0000950170-25-064530.md) | [16.7 d](/filings/0000950170-25-103063.md) | [59.5 d](/filings/0001193125-25-267205.md) | [99.3 d](/filings/0001193125-26-064009.md) | [82.4](/filings/0001193125-26-209195.md) | [37.6 d](/filings/0001193125-26-335156.md) | [66.2 d](/filings/0001193125-25-267205.md) | [57.6 d](/filings/0001193125-26-064009.md) | [27.1](/filings/0001193125-26-209195.md) | [56.8 d](/filings/0001193125-26-335156.md) |
| Capital expenditure | $m | [7.5 d](/filings/0000950170-24-121533.md) | [7.0 d](/filings/0001193125-26-064009.md) | [5.1](/filings/0000950170-25-064530.md) | [6.2 d](/filings/0000950170-25-103063.md) | [8.3 d](/filings/0001193125-25-267205.md) | [4.0 d](/filings/0001193125-26-064009.md) | [1.8](/filings/0001193125-26-209195.md) | [3.1 d](/filings/0001193125-26-335156.md) | [3.6 d](/filings/0001193125-25-267205.md) | [3.5 d](/filings/0001193125-26-064009.md) | [6.5](/filings/0001193125-26-209195.md) | [7.3 d](/filings/0001193125-26-335156.md) |
| Dividends paid | $m | [14.2 d](/filings/0000950170-24-121533.md) | [14.2 d](/filings/0001193125-26-064009.md) | [14.2](/filings/0000950170-25-064530.md) | [14.2 d](/filings/0000950170-25-103063.md) | [14.2 d](/filings/0001193125-25-267205.md) | [14.2 d](/filings/0001193125-26-064009.md) | [14.7](/filings/0001193125-26-209195.md) | [14.6 d](/filings/0001193125-26-335156.md) | [14.6 d](/filings/0001193125-25-267205.md) | [14.5 d](/filings/0001193125-26-064009.md) | [14.9](/filings/0001193125-26-209195.md) | [14.7 d](/filings/0001193125-26-335156.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-23-060317.md) | [0.0 d](/filings/0001193125-26-064009.md) | [0.0](/filings/0000950170-25-064530.md) | [0.0 d](/filings/0000950170-25-103063.md) | [0.0 d](/filings/0001193125-25-267205.md) | [7.5 d](/filings/0001193125-26-064009.md) | [15.0](/filings/0001193125-26-209195.md) | [11.0 d](/filings/0001193125-26-335156.md) | [11.0 d](/filings/0001193125-25-267205.md) | [43.0 d](/filings/0001193125-26-064009.md) | [19.8](/filings/0001193125-26-209195.md) | [21.1 d](/filings/0001193125-26-335156.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [61.3](/filings/0000950170-23-060317.md) | [61.2](/filings/0000950170-24-054516.md) | [61.2](/filings/0000950170-24-091897.md) | [61.3](/filings/0000950170-24-121533.md) | [61.3](/filings/0000950170-25-064530.md) | [61.4](/filings/0000950170-25-103063.md) | [61.4](/filings/0001193125-25-267205.md) | [61.0](/filings/0001193125-26-209195.md) | [60.7](/filings/0001193125-26-335156.md) | [60.5](/filings/0001193125-25-267205.md) | [59.1](/filings/0001193125-26-209195.md) | [58.7](/filings/0001193125-26-335156.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 58,070,577 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335156.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:18 ET. No prices; not investment advice.